Skip to main content Accessibility help
×
Home
  • Print publication year: 2006
  • Online publication date: December 2009

5 - Medical treatment for carotid stenosis

from Background

Summary

Patients with carotid stenosis are at high risk of stroke and acute ischemic events in other vascular territories and require intensive medical treatment. This chapter reviews the evidence for specific medical treatments in patients with carotid stenosis. Antiplatelet agents, cholesterol-lowering drugs and blood-pressure-lowering drugs should be considered in all patients with carotid stenosis. The use of drug combinations has the theoretical advantage of inhibiting platelet activity through more than one pharmacological mechanism, hence potentially conferring a greater antiplatelet effect. Loss of the normal autoregulatory capacity of the cerebral circulation such that cerebral blood flow is directly dependent on perfusion pressure, is common and there has been concern that blood pressure lowering may reduce cerebral perfusion and increase the risk of stroke. Intima-media thickness (IMT) is correlated with the presence of cardiovascular risk factors and possibly with the future risk of vascular events including stroke and myocardial infarction.

Related content

Powered by UNSILO
References
Aikawa, M., Rabkin, E., Sugiyama, S., et al. (2001). An HMG-b-hydroxy-b-methylglutaryl-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases, and tissue factor in vivo, and in vitro. Circulation, 103, 276–83.
Amarenco, P., Bogousslavsky, J., Callahan, A. S., et al. (2003). Design and baseline characteristics of the stroke prevention by aggressive reduction in cholesterol levels (Stroke prevention by aggressive reduction in cholesterol levels) study. Cerebrovascular Disease, 16, 389–95.
Amarenco, P., Labreuche, J., Lavallee, P. and Touboul, P. J. (2004). Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke, 35, 2902–9.
Amin-Hanjani, S., Stagliano, N. E., Yamada, M., et al. (2001). Mevastatin, an HMG-b-hydroxy-b-methylglutaryl-CoA reductase inhibitor, reduces stroke damage and upregulated endothelial nitric oxide synthase in mice. Stroke, 32, 980–6.
Antithrombotic Trialists Collaboration. (2002). Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. British Medical Journal, 324, 71–86.
Bond, R., Rerkasem, K., Cuffe, R. and Rothwell, P. M. (2005). A systematic review of the associations between age and sex and the operative risks of carotid endarterectomy. Cerebrovascular Disease, 20, 69–77.
Clopidogrel versus aspirin in patients at risk of ischemic events Steering Committee. (1996). A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (Clopidogrel versus aspirin in patients at risk of ischemic events). Lancet, 348, 1329–39.
Chimowitz, M. I., Kokkinos, P., Strong, J., et al. (1995). For the Warfarin-Aspirin Symptomatic Intracranial Disease Study Group. The warfarin-aspirin symptomatic intracranial disease study. Neurology, 45, 1488–93.
Chimowitz, M. I., Lynn, M. J., Howlett-Smith, H., et al. (2005). Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. New England Journal of Medicine, 352, 1305–16.
Crisby, M., Nordin-Fredricksson, G., Shah, P. K., et al. (2001). Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques. Implications for plaque stabilization. Circulation, 103, 926–33.
Lorgeril, M., Salen, P., Martin, J. -L., et al. (1999). Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation, 99, 779–85.
Diener, H. C., Bogousslavsky, J., Brass, I. M., et al. (2004). Aspirin and clopidogrel compared with clopidogrel alone after recent ischemic stroke or transient ischemic attack in high-risk patients (Management of atherothrombosis with clopidogrel in high-risk patients): randomised double-blind, placebo-controlled trial. Lancet, 364, 331–7.
Diener, H. C., Cunha, L., Forbes, C., et al. (1996). European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. Journal of the Neurological Sciences, 143, 1–13.
Engelter, S. and Lyrer, P. (2003). Antiplatelet therapy for preventing stroke and other vascular events after carotid endarterectomy. Cochrane Database System Review, CD001458.
European Carotid Surgery Trialists' Collaborative Group. (1991). Medical research council European Carotid Surgery Trial. Interim results for symptomatic patients with severe (70–99%) or with mild (0–29%) carotid stenosis. Lancet, 337, 1235–43.
Fairhead, J. F., Mehta, Z. and Rothwell, P. M. (2005). Population-based study of delays in carotid imaging and surgery and the risk of recurrent stroke. Neurology, 65, 371–5.
Goertler, M., Baeumer, M., Kross, R., et al. (1999). Rapid decline of cerebral microemboli of arterial origin after intravenous acetylsalicylic acid. Stroke, 30, 66–9.
Gorelick, P. B. (1993). Distribution of atherosclerotic cerebrovascular lesions. Effects of age, race, and sex. Stroke, 24, 116–19.
Grubb, R. L. Jr, Derdeyn, C. P., Fritsch, S. M., et al. (1998). Importance of hemodynamic factors in the prognosis of symptomatic carotid occlusion. Journal of the American Medical Association, 280, 1055–60.
Heart Protection Study Collaborative Group. (2002). Medical research council/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk patients: a randomised placebo-controlled trial. Lancet, 360, 7–22.
Heart Protection Study Collaborative Group. (2004). Effects of cholesterol lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high risk conditions. Lancet, 363, 757–7.
Hedblad, B., Wikstrand, J., Janzon, L., Wedel, H. and Berglund, G. (2001). Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: main results from the Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS). Circulation, 103, 1721–26.
Hooper, L., Bartlett, C., Davey Smith, G. and Ebrahim, S. (2002). Systematic review of long term effects of advice to reduce dietary salt in adults. British Medical Journal, 325, 628–32.
Hosomi, N., Mizushige, K., Ohyama, H., et al. (2001). Angiotensin-converting enzyme inhibition with enalapril slows progressive intima-media thickening of the common carotid artery in patients with non-insulin-dependent diabetes mellitus. Stroke, 32, 1539–45.
Kaplan, E. D. (2003). Association between homocysteine levels and risk of vascular events. Drugs Today (Barc), 39, 175–92.
Kennedy, J., Eliasziw, M., Hill, M. D. and Buchan, A. M. (2003). The Fast Assessment of Stroke and Transient Ischemic Attack to prevent Early Recurrence (Fast assessment of stroke and transient ischemic attack to prevent early recurrence) Trial. Seminars in Cerebrovascular Diseases and Stroke, 3, 25–30.
Kodama, M., Yamasaki, Y., Sakamoto, K., et al. (2000). Antiplatelet drugs attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes. Thrombosis Research, 97, 239–45.
Langenfeld, M. R., Forst, T., Hohberg, C., et al. (2005). Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study. Circulation, 111, 2525–31.
Laufs, U., Gertz, K., Dirnagl, U., et al. (2002). Rosuvastatin, a new HMG-b-hydroxy-b-methylglutaryl-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice. Brain Research, 28, 23–30.
Leonardi-Bee, J., Bath, P. M., Bousser, M. G., et al. (2005). Dipyridamole in Stroke Collaboration (DISC). Dipyridamole for preventing recurrent ischemic stroke and other vascular events: a meta-analysis of individual patient data from randomized controlled trials. Stroke, 36, 162–8.
Lonn, E., Yusuf, S., Dzavik, V., et al. (2001). Effects of ramipril and vitamin E on atherosclerosis: the Study to Evaluate Carotid Ultrasound Changes in Patients Treated With Ramipril and Vitamin E (SECURE). Circulation, 103, 919–25.
Lovett, J. K., Coull, A., Rothwell, P. M., on behalf of the Oxford Vascular Study. (2004). Early risk of recurrent stroke by aetiological subtype: implications for stroke prevention. Neurology, 62, 569–74.
Mancini, G. B., Dahlof, B. and Diez, J. (2004). Surrogate markers for cardiovascular disease: structural markers. Circulation, 109 (Suppl. 1), 22–30.
Markus, H. S., Droste, D. W., Kaps, M., et al. (2005). Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using Doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (Clopidogrel and aspirin for reduction of emboli in symptomatic carotid stenosis) trial. Circulation, 111, 2233–40.
Mercuri, M., Bond, M. G., Sirtori, C. R., et al. (1996). Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic Mediterranean population: The Carotid Atherosclerosis Italian Ultrasound Study. American Journal of Medicine, 101, 627–34.
Molyneux, A. (2004). Nicotine replacement therapy. British Medical Journal, 328, 454–6.
North American Symptomatic Carotid Endarterectomy Trial Collaborators (1991). Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. New England Journal of Medicine, 325, 445–53.
Pignoli, P., Tremoli, E., Poli, A., Oreste, P. and Paoletti, R. (1986). Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. Circulation, 74, 1399–406.
Progress Collaborative Group. (2001). Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet, 358, 1033–41.
Prospective Studies Collaboration (1995). Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Lancet, 346, 1647–53.
Rosenson, R. S. (2004). Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities. Atherosclerosis, 173, 1–12.
Rothwell, P. M., Eliasziw, M., Gutnikov, S. A., Warlow, C. P. and Barnett, H. J. (2004). Carotid Endarterectomy Trialists Collaboration Endarterectomy for symptomatic carotid stenosis in relation to clinical subgroups and timing of surgery. Lancet, 363, 915–24.
Rothwell, P M., Howard, S. C. and Spence, D. (2003). Relationship between blood pressure and stroke risk in patients with symptomatic carotid occlusive disease. Stroke, 34, 2583–90.
Rothwell, P. M., Mehta, Z., Howard, S. C., Gutnikov, S. A. and Warlow, C. P. (2005). From subgroups to individuals: general principles and the example of carotid endartectomy. Lancet, 365, 256–65.
Rothwell, P. M., Warlow, C. P. on behalf of the European carotid surgery Collaborators. (1999). Prediction of benefit from carotid endarterectomy in individual patients: A risk-modelling study. Lancet, 353, 2105–10.
Stiller, C. A. (1994). Centralised treatment, entry to trials and survival. British Journal of Cancer, 70, 352–62.
Stroke Prevention in Reversible Ischemia Trial (Stroke prevention in reversible ischemia trial) Study Group. (1997). A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. Annals of Neurology, 42, 857–65.
Takemoto, M.and Liao, J. K. (2001). Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arteriosclerosis, Thrombosis and Vascular Biology, 21, 1712–19.
Thiele, B. L., Young, J. V., Chikos, P. M., Hirsch, J. H. and Strandness, D. E. (1980). Correlation of arteriographic findings and symptoms in cerebrovascular disease. Neurology, 30, 1041–6.
Toole, J. F., Malinow, M. R., Chambless, L. E., et al. (2004). Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. Journal of the American Medical Association, 291, 565–75.
Grond, J., Balm, R., Kappelle, J., Eikelboom, B. C. and Mali, W. P. (1995). Cerebral metabolism of patients with stenosis or occlusion of the internal carotid artery. Stroke, 26, 822–8.
Vaughan, C. J., Murphy, M. B. and Buckley, B. M. (1996). Statins do more than just lower cholesterol. Lancet, 348, 1079–82.
VITATOPS Trial Study Group. (2002). The VITATOPS (Vitamins to Prevent Stroke) Trial: rationale and design of an international, large, simple, randomised trial of homocysteine-lowering multivitamin therapy in patients with recent transient ischaemic attack or stroke. Cerebrovascular Disease, 13, 120–6.
Warfarin Aspirin Recurrent Stroke Study Group. (2001). A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. New England Journal of Medicine, 345, 1444–51.
Waters, D. D., Schwartz, G. G., Olsson, A. G., et al. (2002). Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction. A Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy. Circulation, 106, 1690–5.
Wennberg, D. E., Lucas, F. L., Birkmeyer, J. D., Bredenberg, C. E. and Fisher, E. S. (1998). Variation in carotid endarterectomy mortality in the Medicare population: trial hospitals, volume, and patient characteristics. Journal of the American Medical Association, 279, 1278–81.